CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 133 enrolled
Drug / intervention
Fluarix™ +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00538213
NCT00538213Phase 2Completed
CompareCT.gov

Reactogenicity and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK576389A in Elderly Adults (≥66 Years) Previously Vaccinated With the Same Candidate Vaccine. Fluarix™ Will be Used as Reference

GlaxoSmithKline·interventional·Posted Oct 2, 2007·Updated Jun 8, 2018

In Brief

A Phase 2 clinical trial evaluating Fluarix™ and GSK Bio's Influenza Vaccine GSK576389A for Influenza. Completed, enrolled 133 participants across 1 site.

Detailed Summary

Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after repeated vaccine administration. In this study, the subjects previously enrolled in study 104887 will receive a dose with the 2007-2008 season's formulations of Fluarix or GSK576389A. Only subjects who were previously enrolled in study 104887 are eligible for participation in this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesBelgium
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2, 2007
Enrollment StartOct 15, 2007
Primary CompletionNov 1, 2007
Study CompletionNov 28, 2007
TodayJul 2, 2026
Enrollment to primary: 16 daysPosted 18.8 years ago

Interventions

Fluarix™biological

Single dose, Intramuscular injection

GSK Bio's Influenza Vaccine GSK576389Abiological

Single dose, Intramuscular injection